RegulatoryJun 23, 2026, 06:01 AM
Skye Bioscience Moves to Nasdaq Capital Market Due to Equity Deficiency
AI Summary
Skye Bioscience, Inc. received approval to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective June 23, 2026. This move follows the company's non-compliance with the Nasdaq Global Market's $10,000,000 minimum stockholders' equity standard, as its equity was $9,011,804 as of March 31, 2026. The Nasdaq Capital Market requires a lower $3,000,000 minimum stockholders' equity.
Key Highlights
- Skye Bioscience's stockholders' equity was $9,011,804 as of March 31, 2026.
- The company did not meet Nasdaq Global Market's $10,000,000 minimum stockholders' equity standard.
- Approved to transfer to Nasdaq Capital Market, which requires a $3,000,000 minimum stockholders' equity.
- Transfer is effective June 23, 2026, with the ticker symbol SKYE remaining unchanged.
- Company also received notice for not meeting the $1.00 minimum bid price requirement.
- Initial compliance period for the minimum bid price requirement ends September 14, 2026.
Price Impact
More from SKYE